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Objectives This study investigated the influence of baseline and worsening renal function (WRF) on the efficacy of spirono-
lactone in patients with severe heart failure (HF).
Background Renal dysfunction or decline in renal function is a known predictor of adverse outcome in patients with HF, and
treatment decisions are often on the basis of measures of renal function.
Methods We used data from the RALES (Randomized Aldactone Evaluation Study) in 1,658 patients with New York Heart
Association functional class III or IV HF and an ejection fraction 35%. Participants were randomized to spirono-
lactone 25 mg, which could be titrated to 50 mg, or placebo daily. Renal function (estimated glomerular filtra-
tion rate [eGFR]) was estimated by the Modification of Diet in Renal Disease equation. Worsening renal function
was defined as a 30% reduction in eGFR from baseline to 12 weeks post-randomization.
Results Individuals with reduced baseline eGFR exhibited similar relative risk reductions in all-cause death and the com-
bined endpoint of death or hospital stays for HF as those with a baseline eGFR 60 ml/min/1.73 m2 and
greater absolute risk reduction compared with those with a higher baseline eGFR (10.3% vs. 6.4%). More-
over, WRF (17% vs. 7% for spironolactone and placebo groups, p  0.001) was associated with an in-
creased adjusted risk of death in the placebo group (hazard ratio: 1.9, 95% confidence interval: 1.3 to 2.6)
but not in those randomized to spironolactone (hazard ratio: 1.1, 95% confidence interval: 0.79 to 1.5,
p interaction  0.009). The risk of hyperkalemia and renal failure was higher in those with worse baseline
renal function and those with WRF, particularly in the spironolactone arm, but the substantial net benefit of
spironolactone therapy remained.
Conclusions The absolute benefit of spironolactone was greatest in patients with reduced eGFR. Worsening renal function
was associated with a negative prognosis, yet the mortality benefit of spironolactone was maintained. (J Am
Coll Cardiol 2012;60:2082–9) © 2012 by the American College of Cardiology Foundation
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accepted July 24, 2012.Elevated aldosterone concentrations have known detrimen-
tal effects on the myocardium and renal vasculature (1). Two
pivotal clinical trials in heart failure (HF) have demon-
strated benefit with aldosterone receptor antagonists (2,3),
and current HF treatment guidelines recommend the use of
a mineralocorticoid receptor antagonist (MRA) in patients
See page 2090
with moderately severe to severe symptoms of HF and
reduced left ventricular ejection fraction and in patients after
acute myocardial infarction (MI) complicated by left ven-
tricular systolic dysfunction and HF (4,5). More recently,
the EMPHASIS-HF study (Eplerenone in Mild Patients
p
t
c
d
c
c
r
w
p
i
c
a
i
A
V
w
r
(
c
p
A
S
w
v
m
p
l
E
r
p
p
s
p
p
M
P
d
t
m
N
P
e
a
e
l
l

m
t
c
p
d
d
s
w
m
i
1
p
a
a
p
C
d
p
s
(
m
S
a
2083JACC Vol. 60, No. 20, 2012 Vardeny et al.
November 13, 2012:2082–9 Spironolactone and Renal Dysfunction in HFHospitalization and Survival Study in Heart Failure) further
supported the use of these agents in HF patients with
milder HF symptoms (6).
Mineralocorticoid receptor antagonists are not recommended
when the serum creatinine is raised above 2.5 mg/dl (or when
creatinine clearance is 30 ml/min) or in those with serum
otassium levels above 5.0 mmol/l. Renal dysfunction, even
ransient, is common in HF patients and is a known predictor of
ardiovascular outcomes and mortality in patients with cardiac
isease. Worsening renal function (WRF), otherwise known as
ardiorenal syndrome type 2 (7), is defined as increases in
reatinine or reductions in estimated glomerular filtration
ate (eGFR). Worsening renal function has been associated
ith adverse outcomes in patients with HF, underuse of
roven agents, and even discontinuation of beneficial med-
cation (8,9).
Nevertheless, rises in creatinine or declines in eGFR are
ommon in patients receiving inhibitors of the renin-
ngiotensin-aldosterone system, possibly due to alterations
n renal hemodynamic status (10). In both the Survival
nd Ventricular Enlargement (11) and Studies of Left
entricular Dysfunction (12) trials, worsening creatinine
as not associated with adverse outcome in patients
eceiving the angiotensin-converting enzyme inhibitor
ACEI) captopril, whereas it was associated with in-
reased risk in those receiving placebo. Recent data in
ost-MI patients from the EPHESUS (Eplerenone Post-
cute Myocardial Infarction Heart Failure Efficacy and
urvival Study) showed that early WRF with eplerenone
as associated with an increased risk of adverse cardio-
ascular outcomes, yet the benefit of eplerenone was
aintained (13). The prognostic significance of WRF in
atients with moderate to severe HF receiving spirono-
actone, however, remains unknown.
We used data from the RALES (Randomized Aldactone
valuation Study) to determine the influence of baseline
enal function on efficacy of the MRA spironolactone in HF
atients and the prognostic importance of WRF in HF
atients receiving an aldosterone antagonist. We hypothe-
ized that WRF would be associated with a more benign
rognosis in patients receiving an MRA compared with
atients receiving placebo.
ethods
articipants. The RALES study was a double-blind, ran-
omized, placebo controlled trial that was designed to assess
he efficacy of spironolactone on prevention of all-cause
ortality and cardiac-related hospital stays in patients with
ew York Heart Association functional class III or IV HF.
articipants were enrolled if they had a left ventricular
jection fraction 35% while taking background ACEIs
nd diuretics. Exclusion criteria were primary valvular dis-
ase, congenital heart disease, unstable angina, liver failure,
isting for cardiac transplant, active cancer, or any other
ife-threatening disease. Patients with serum creatinine2.5 mg/dl or potassium 5
mol/l were also excluded. Par-
icipants were randomized to re-
eive spironolactone 25 mg or
lacebo daily. After 8 weeks, the
ose could be increased to 50 mg
aily for patients with signs and
ymptoms of progression of HF
ithout evidence of hyperkale-
ia. Serum potassium and creat-
nine were measured at 4, 8, and
2 weeks during the titration
hase and every 3 months there-
fter during the study and were
vailable in 1,658 of the 1,663
atients enrolled in the study.
oncomitant treatment with
igoxin and vasodilators was allowed, and the use of
otassium-sparing diuretics was not permitted. Oral potas-
ium supplement use was discouraged unless hypokalemia
defined as a serum potassium concentration of 3.5
mol/l) developed.
tatistical analyses. We defined reduced baseline eGFR
s 60 ml/min/1.73 m2 and WRF as a 30% reduction in
eGFR (14) from baseline (calculated by the Modification of
Diet in Renal Disease equation) at any time during the
titration phase (through week 12) after randomization. Baseline
demographic data between participants with eGFR 60
ml/min/1.73 m2 and those with eGFR 60 ml/min/1.73 m2
and between those with WRF and those without WRF
were compared with identify potential differences. Between-
group assessments were performed with t tests for contin-
uous variables and chi-square or Fisher exact tests, as
appropriate, for categorical variables. Hyperkalemia was
defined as a potassium level 5.5 mmol/l at any visit or a
serious adverse event related to hyperkalemia at any time
during study follow-up. For WRF, we performed a sensi-
tivity analysis with another definition of 0.3 mg/dl in-
crease in serum creatinine with qualitatively similar results
(not shown).
Cox proportional hazards regression models were used to
examine associations between baseline renal function and
all-cause mortality and the combined endpoint of death or
HF hospital stay as well as the effectiveness of treatment
with spironolactone. Paired t-tests were used to assess
differences in eGFR by treatment arm during the titration
phase. A WRF during the titration phase (through week 12)
was related to subsequent long-term outcomes in a land-
mark analysis. We further performed these analyses, adjust-
ing for the following covariates: age, sex, race, HF etiology,
history of diabetes, MI, angina, hypertension, baseline
blood pressure, ejection fraction, baseline potassium and
creatinine, treatment, baseline medications (aspirin, ACEI/
angiotensin receptor blocker [ARB], beta-blocker, loop
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
ARB  angiotensin
receptor blocker
CI  confidence interval
eGFR  estimated
glomerular filtration rate
HF  heart failure
MI  myocardial infarction
MRA  mineralocorticoid
receptor antagonist
WRF  worsening renal
functiondiuretic, digoxin), and eGFR or WRF  treatment inter-
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11, StataCorp, College Station, Texas).
Results
Of 1,658 patients included in these analyses, 792 (48%) had
a baseline eGFR 60 ml/min/1.73 m2, and 866 (52%) had
a baseline eGFR 60 ml/min/1.73 m2. Baseline character-
istics by eGFR are shown in Table 1. Participants with a
baseline eGFR 60 ml/min/1.73 m2 were older, more
ikely to be female, diabetic, Caucasian, and were more
ikely to have an ischemic etiology for HF and less likely to
e taking aspirin, diuretics, and digoxin at study entry.
WRF occurred in 199 (12%) patients during titration
Table 2). The percentage of patients with WRF was
ignificantly higher in the spironolactone group than in the
lacebo group (17% vs. 7%, p  0.001). Although eGFR
as similar in the spironolactone and placebo groups at
aseline (65.3  23.1 vs. 64.5  22.8, p  0.46), eGFR
eclined at 4 weeks in the spironolactone arm (62.6  23.8
s. 65.5  26.1, p  0.02) and remained reduced at the end
f titration (62.4  25.0 vs. 65.4  23.6, p  0.02). Renal
unction continued to decline in both groups; however,
ifferences in eGFR between spironolactone and placebo
roups were no longer significant by 6 months after ran-
omization. The proportion of patients with WRF was
imilar in those who started with baseline eGFR below and
bove 60 ml/min/1.73 m2 (11% vs. 15%, p 0.22). Patients
with worsening eGFR were older and more likely to be
female. There were no significant differences in baseline
Baseline Characteristics by eGFRTable 1 Baseline Characteristics by eGFR
Characteristic
eGFR* <60
(n  792)
eGFR >60
(n  866) p Value
Mean eGFR 47.1  8.9 81.1  19 0.001
Age, yrs 70.0 (9.4) 61.2 (12.4) 0.001
Men 69.4 76.7 0.001
EF 25.2 (6.7) 25.6 (6.7) 0.23
Caucasian race 93.2 80.5 0.001
Ischemic etiology 63.3 47.1 0.001
NYHA functional class III or IV 69.8/29.8 71.1/28.4 0.58
BP, mm Hg 122.6/73.6 121.9/75.5 0.47/0.001
History of hypertension 27.5 20 0.001
Diabetes 26.2 18.5 0.001
History of angina 7.6 5.9 0.17
History of MI 33.8 23.4 0.001
Medications
Aspirin 39.7 33.1 0.006
ACEI/ARB 94.2 96.8 0.01
Beta blocker 10.7 9.9 0.6
Diuretic 87.8 92.3 0.001
Digoxin 67.1 78.8 0.001
K, mmol/l 4.2 (0.5) 4.2 (0.4) 0.06
SCr, mg/dl 1.5 (0.3) 1.0 (0.2) 0.001
Values are mean  SD or %. *Estimated glomerular filtration rate (eGFR) is in ml/min/1.73 m2.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; BP 0
lood pressure; EF  ejection fraction; K  potassium supplement; MI  myocardial infarction;
YHA  New York Heart Association functional class; SCr  serum creatinine.characteristics between the placebo and spironolactone
groups in patients with or without WRF. Of note, blood
pressure at the end of titration (week 12) was not different
between participants with and without WRF. In addition,
patients with WRF were more likely to have received
ACEIs or ARBs (34% vs. 26%, p  0.01), digoxin (22% vs.
14%, p  0.004), or loop diuretics (41% vs. 33%, p  0.02)
during titration, although this did not differ by treatment
group.
Outcomes by baseline eGFR and WRF. Baseline eGFR
lower than 60 ml/min/1.73 m2 was associated with similarly
increased risk for mortality in both treatment groups
(Fig. 1A, Table 3), even adjusting for baseline covariates.
The risk for the combined endpoint of death or HF hospital
stay was similarly increased in crude estimates in both
groups (Fig. 1B, Table 3) but not significantly different
when adjusted for baseline covariates. There were a total of
670 deaths (386 placebo, 284 spironolactone), similarly
distributed between eGFR  or 60 ml/min/1.73 m2 (402
s. 436 deaths). For the combined endpoint of all-cause
eath or HF hospital stays, there were 909 events (522
lacebo, 387 spironolactone); 483 for eGFR 60, and 422
or those with eGFR 60 ml/min/1.73 m2. At the end of
itration (12 weeks), 63 deaths occurred in the placebo
roup, and 54 deaths occurred in the spironolactone group.
or HF hospital stays, 105 occurred in the placebo group,
nd 51 occurred in the spironolactone group by the end of
itration. When stratifying by baseline eGFR, 80 deaths
ccurred in eGFR 60, and 37 occurred in those with
GFR 60. For HF hospital stays, 74 occurred in eGFR
60, whereas 81 occurred in eGFR 60. Baseline renal
unction, modeled as a continuous or categorical variable, did
ot modify the benefits of spironolactone, with an approxi-
ately 30% relative risk reduction for mortality regardless of
aseline eGFR, and a similar risk reduction for the combined
ndpoint of death or HF hospital stay (Fig. 1A, Table 4). The
bsolute risk reduction for mortality was substantially higher
n patients with worse baseline eGFR (10.3% vs. 6.4%), and
he absolute risk reduction for death or HF hospital stay at
years was 13.7% in the lower eGFR group, compared with
2.7% in the higher eGFR group.
Worsening renal function, defined as a 30% reduction in
GFR during the titration period, was associated with an
ncreased subsequent long-term risk of death in the placebo
roup, even when adjusted for baseline covariates (hazard
atio: 1.9, 95% confidence interval [CI]: 1.3 to 2.6) (Figs. 2A
nd 2B, Table 3). In contrast, in the spironolactone arm,
RF was not associated with an increased risk for death,
ith a highly significant interaction between treatment and
RF with respect to outcome (hazard ratio: 1.1, 95% CI:
.79 to 1.5; p interaction  0.009). For the combined
utcome of death or hospital stay for HF (Figs. 2C and 2D,
able 3), WRF was similarly associated with a significantly
ncreased risk in the placebo group, and this risk was also
ubstantially attenuated in the treatment arm (p-interaction
.04). Patients randomized to spironolactone derived ben-
groups
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November 13, 2012:2082–9 Spironolactone and Renal Dysfunction in HFefit whether or not renal function worsened during titration,
with no attenuation of the approximately 30% reduction in
mortality, and mild attenuation in the combined endpoint,
when making even the most conservative comparison be-
tween the treatment group with WRF and the placebo
group without WRF (Fig. 2, Table 4).
Hyperkalemia or adverse event rates by baseline eGFR
and WRF. Hyperkalemia defined as potassium 5.5
mmol/l at a study visit or a hyperkalemia adverse event at
Figure 1 Baseline Mortality and Hospital Stay
(A) Mortality by baseline estimated glomerular filtration rate (eGFR) and randomize
treatment. Baseline renal function did not modify the efficacy of spironolactone on
Baseline Characteristics by WRF and TreatmentTable 2 Baseline Characteristics by WRF and Treatment
Characteristic
No WRF
All Subjects
Placebo
(n  781)
Spiro
(n  68
Age, yrs 65.0 11.8 65.2 11.8 65.3 1
Men 74.4 73.8 75.4
EF 25.3 6.7 25.2 6.8 25.6 6
Caucasian race 86.5 86.4 86.5
Ischemic etiology 55.0 54.9 55.2
Hypertension 24.3 24.7 23.8
Diabetes 21.9 23.3 20.3
History of angina 6.7 5.8 7.6
History of MI 28.7 29.8 27.5
Baseline BP (mm Hg) 122.2/74.7 121.6/74.5 122.8/7
Week 12 BP (mm Hg) 122.3/74.3 123.7/75.0 120.8/7
Medications at baseline
Aspirin 36.8 37.9 35.4
ACE/ARB 95.3 95.1 95.5
Beta-blocker 10.5 10.4 10.7
Diuretic 90.4 90.1 90.8
Digoxin 72.3 70.9 73.9
K, m/l 4.2 0.4 4.2 0.4 4.2 0
SCr, mg/dl 1.3 0.4 1.2 0.4 1.2 0
eGFR, ml/min/1.73 m2 64.0 21.8 63.8 21.9 64.2 2
Values are mean  SD or %. *Comparison between no worsening renal function (WRF) and WRF
Spiro  spironolactone; other abbreviations as in Table 1.any time during follow-up occurred more frequently in
participants with reduced baseline eGFR and particularly
more frequently in those with reduced eGFR who received
spironolactone compared with those with reduced eGFR
receiving placebo (25.6% vs. 8.5%, p  0.001) (Table 5).
The increased risk of hyperkalemia due to spironolactone
was higher in those with lower eGFR compared with those
with higher eGFR (odds ratio: 1.53, 95% CI: 1.16 to 2.02).
Those with baseline eGFR 60 who were taking spirono-
tment. (B) Mortality and hospital stay for heart failure (HF) by baseline eGFR and
use mortality and the combined endpoint of mortality and hospital stays for HF.
WRF
p Value*All Subjects
Placebo
(n  60) (7%)
Spiro
(n  139) (17%)
66.7 12.3 65.6 12.3 67.2 12.6 0.07
63.3 63.3 63.3 0.001
25.6 7.0 24.8 6.9 24.9 7.0 0.60
87.4 88.3 87.1 0.68
51.8 41.7 56.1 0.34
18.6 10.0 22.3 0.08
24.6 21.7 25.9 0.38
7.0 1.7 9.4 0.84
26.6 18.3 30.2 0.54
122.4/74.1 118.8/73.4 124.0/74.4 0.9, 0.52
121.1/73.3 117.6/73.2 122.4/73.3 0.46, 0.21
31.7 33.3 30.9 0.15
97.5 96.7 97.8 0.16
8.5 8.3 8.6 0.38
89.5 93.3 87.8 0.67
78.9 85.0 76.3 0.05
4.2 0.5 4.1 0.5 4.2 0.5 0.04
1.2 0.4 1.1 0.4 1.2 0.4 0.001
71.3 29.7 73.1 31.1 70.6 29.1 0.001
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discontinuation during titration.
Patients with WRF had a higher overall risk of hyperka-
lemia, and this risk was even greater in those receiving
spironolactone compared with those who received placebo
(Table 5). The increased risk of hyperkalemia in patients
receiving spironolactone was most evident if renal function
worsened (odds ratio: 3.6, 95% CI: 1.5 to 8.6, compared
with participants receiving spironolactone without WRF).
Finally, patients with WRF were more likely to have their
study drug dose reduced or discontinued during the titration
period, although this also appeared true whether they were
receiving placebo or spironolactone.
Discussion
In this analysis of patients with moderately severe to severe
HF randomized to an MRA or placebo, individuals with
reduced baseline eGFR exhibited similar relative risk reduc-
tions in all-cause death and the combined endpoint of death
or hospital stays for HF as those with a baseline eGFR60
ml/min/1.73 m2 and greater absolute risk reduction com-
ared with those with a higher baseline eGFR. Moreover,
RF—defined in this study as a 30% reduction in baseline
GFR—was associated with an increased risk of death in
he placebo group but not in those randomized to spirono-
actone, and the risk of the combined endpoint of death or
F hospital stay in those with WRF was increased in the
lacebo group but markedly attenuated in those receiving
pironolactone. The risk of hyperkalemia was higher in
hose with worse baseline renal function and those with
RF, particularly in the spironolactone arm, but there
emained substantial net benefit.
Spironolactone was associated with an approximate 30%
eduction in all-cause mortality in the RALES study, and
he more selective MRA eplerenone has shown similar
Risk Associated With Baseline eGFR <60 ml/min/1.73 m2 and WTable 3 Risk Associated With Baseline eGFR <60 ml/min/1.7
Risk Associated With eG
Placebo (n  405)
Mortality Crude HR 1.57 (1.28–1.91)
Adjusted* HR 1.29 (1.04–1.61)
Death or HF hospital stay Crude HR 1.40 (1.18–1.67)
Adjusted* HR 1.08 (0.82–1.42)
*Models adjusted for age, sex, race, heart failure (HF) etiology, history of diabetes, MI, angina, hy
HR  hazard ratio; other abbreviations as in Tables 1 and 2.
Efficacy of Spironolactone by Baseline eGFR and by WRFTable 4 Efficacy of Spironolactone by Baseline eGFR and by W
Efficacy of Spironolactone by Bas
eGFR <60 ml/min/1.73 m2
(n  792)
eGFR >
Mortality 0.68 (0.56–0.84) 0
Death or HF hospital stay 0.67 (0.56–0.81) 0HF  heart failure; eGFR  estimated glomerular filtration rate; WRF  worsening renal function.enefit in several other studies. In this analysis, we noted a
imilar relative benefit and greater absolute benefit in
atients with baseline eGFR 60 ml/min/1.73 m2 treated
ith spironolactone, a finding that is similar to that ob-
erved in post-MI patients with lower eGFR treated with an
CEI (15) and in a small study suggesting improvement in
yocardial systolic and diastolic left ventricular function in
atients with chronic kidney disease when an MRA was used
n addition to ACEIs or ARBs (16,17). Although we observed
n increased risk of adverse events, particularly hyperkalemia,
n these patients, there was still a substantial net benefit to the
se of MRAs in HF patients with reduced eGFR.
Although WRF during the titration phase occurred more
requently in patients randomized to spironolactone, the
isk associated with this worsening was greatest in patients
n the placebo group and was markedly attenuated in those
aking spironolactone. Indeed, WRF was not associated
ith an increased risk for mortality in patients randomized
o spironolactone, and the risk for death or HF hospital stay
as markedly attenuated in those receiving active treatment.
hese data suggest that elevation of creatinine (and wors-
ning of GFR) in the setting of spironolactone therapy
as far less prognostic importance than worsening of
enal function without inhibiting the renin-angiotensin-
ldosterone system, a finding that is similar to those seen
ith ACE inhibition post-MI and in HF (11,12). These
ndings suggest that the reduction in eGFR associated with
enin-angiotensin-aldosterone inhibition do not necessarily
eflect kidney injury but might result from MRA-induced
eduction in blood pressure affecting renal blood flow, a
otion that is further supported by the lack of worsening of
enal function after an initial relatively early decline seen in
oth the EPHESUS (13) and RALES studies.
A number of potential mechanisms might explain the
enefit of MRAs in the context of renal dysfunction, indepen-
and WRF
0 ml/min/1.73 m2 Risk Associated With Worsening eGFR
Spiro (n  392) Placebo (n  60) Spiro (n  139)
R 1.48 (1.17–1.87) HR 1.8 (1.3–2.5) HR 0.99 (0.72–1.3)
R 1. 38 (1.07–1.79) HR 1.9 (1.3–2.6) HR 1.1 (0.79–1.5)
R 1.47 (1.20–1.80) HR 1.84 (1.38–2.47) HR 1.23 (0.96–1.59)
R 0.92 (0.66–1.26) HR 1.82 (1.34–2.46) HR 1.37 (1.05–1.79)
ion, baseline BP, EF, baseline potassium and creatinine, treatment, and baseline medications.
GFR
Efficacy of Spironolactone Comparing Treatment Group
With WRF With Placebo Group Without WRF
l/min/1.73 m2
866)
.57–0.90) 0.72 (0.54–0.98)
.52–0.77) 0.82 (.64–1.04)RF3 m2
FR <6
H
H
H
HRF
eline e
60 m
(n 
.71 (0
.64 (0
w2087JACC Vol. 60, No. 20, 2012 Vardeny et al.
November 13, 2012:2082–9 Spironolactone and Renal Dysfunction in HFdent of the potential hemodynamic effects. Up-regulation of
mineralocorticoid receptor density and activity in the heart and
kidney might play an important role in aldosterone-mediated
organ damage (18,19). Aldosterone induces proteinuria, glo-
merular mesangial injury, and tubulointerstitial fibrosis in rat
models, and treatment with MRAs prevented renal injury
secondary to aldosterone administration (20,21). Additionally,
the incidence and magnitude of proteinuria or albuminuria are
higher among patients with primary aldosteronism compared
with patients with essential hypertension (22,23). The use of
an MRA alone or in combination with ACE inhibition or
Figure 2 Kaplan-Meier Curves and Forest Plots for WRF
(A) Kaplan-Meier curves for all-cause mortality by treatment and worsening renal f
ment group; (C) Kaplan-Meier curves for combined endpoint of death or heart failu
with WRF in each treatment group. HR  hazard ratio.
Adverse Events and Drug Discontinuation During TitrationTable 5 Adverse Events and Drug Discontinuation During Titrat
Baseline eGFR <60
PL
(n  402)
SP
(n  390)
Hyperkalemia (K 5.5 mmol/l or AE)* 8.5% 25.6%
OR† 3.7 (2.5–5.7)
Dose reduction or discontinuation during titration 3.0% 6.7%
OR 2.3 (1.2–4.7)
*Variable was defined as hyperkalemia5.5mmol/l or an investigator-reported adverse event (AE)
ithin each category of renal function.
eGFR  estimated glomerular filtration rate; K  potassium; OR  odds ratio; WRF  worsening renaARB therapy was shown to produce additive effects to the
reduction of proteinuria in small randomized studies, which
could suggest that aldosterone might play an important role in
causing renal injury (24–26). Whether these mechanisms
account for the preservation of the benefit of MRAs in HF
patients remains unclear, and it is likely that improved out-
comes in patients with renal dysfunction are more attributable
to a reduction in cardiac fibrosis and remodeling similar to
patients with normal renal function.
Hyperkalemia is a well-recognized adverse outcome in
patients treated with inhibitors of the renin-angiotensin-
(WRF) group; (B) forest plot of risk for death in those with WRF in each treat-
pital stay by treatment and WRF group; (D) forest plot of risk for death in those
seline eGFR >60 No WRF WRF
L
436)
SP
(n  430)
PL
(n  781)
SP
(n  683)
PL
(n  60)
SP
(n  139)
0% 15.4% 6.7% 18.2% 13.3% 30.2%
OR 2.9 (1.8–4.6) OR 3.1 (2.2, 4.4) OR 3.8 (1.2, 6.4)
6% 2.1% 1.8% 3.2% 8.3% 9.3%
R 1.3 (0.48–3.5) OR 1.8 (0.9–3.6) OR 1.1 (0.4–3.3)
ing at any time during the trial; †comparison between placebo (PL) and spironolactone (SP) groupsunction
re hosion
Ba
P
(n 
6.
1.
O
, occurrl function.
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for hyperkalemia in patients with reduced baseline renal
function and in those with WRF after spironolactone.
Higher rates of hyperkalemia and related adverse events
have been noted in clinical practice compared with clinical
trials (27), a finding that might be secondary to less close
monitoring, more frequent dietary indiscretions, or use of
concomitant medications. These findings underscore the
importance of close monitoring of electrolytes with MRAs,
particularly in patients with renal dysfunction, and the
careful assessment of risk versus benefit of MRAs in the
setting of rising potassium levels.
Study limitations. Because this analysis was not pre-
specified, the results should be interpreted with caution. In
particular, a few of the subgroups in this analysis had small
sample sizes, therefore point estimates noted are not defin-
itive. However, these results are consistent with those from
the EPHESUS study, which tested eplerenone in a post-MI
HF population, and with those from the SAVE (Survival
And Ventricular Enlargement) and SOLVD (Studies of
Left Ventricular Dysfunction) studies, in which an ACEI
was tested in a post-MI population and HF populations.
Although we defined WRF as a 30% reduction in eGFR,
other definitions have been used in prior analyses. None-
theless, we performed a sensitivity analysis exploring an
alternate definition of WRF, defined as a 0.3-mg/dl
increase in creatinine, and noted qualitatively similar results
(data not shown). Measurements of serum creatinine were
not blinded during this study. As such, imbalances in the
use ACEIs could have occurred between placebo and
spironolactone groups such that more subjects in the pla-
cebo group received lower or no doses of ACEIs due to dose
adjustments in response to rising serum creatinine. This
might have accounted, in part, for the attenuation in risk
noted in the spironolactone group. The RALES study
excluded individuals with baseline serum creatinine 2.5
mg/dl (eGFR 30 ml/min) and those with serum potas-
sium levels 5.0 mmol/l. We cannot extrapolate these
results to patients with more severe renal dysfunction or
eGFR 30 ml/min. We could not fully adjust for all
potential confounding factors to worsening renal function in
our statistical models, such as hospital stays, exposure to
contrast or other nephrotoxic agents, or occurrence of acute
renal injury. Because more hospital stays occurred in the
placebo group, these other factors could have had a greater
role in contributing to the outcomes. Beta-blocker usage in
the RALES study was low, and beta blockers are known to
enhance the risk for hyperkalemia and might affect the relative
benefit of MRAs. As such, it is unclear whether the same
degree of benefit among those with renal dysfunction and
WRF would have been observed if more participants were also
receiving beta blockers. Finally, in this analysis, we assessed
WRF only during the titration period of the study, although
our data suggest that declines in renal function associated with
spironolactone occurred early in the course of treatment.Conclusions
We found that in patients with advanced HF, those with
reduced baseline eGFR receiving spironolactone exhibited
similar risk reduction in all-cause mortality and the com-
bined outcome of all-cause mortality and hospital stay for
HF, compared with patients with higher baseline eGFR.
Moreover, individuals randomized to spironolactone de-
rived benefit, regardless of whether renal function worsened
during the titration period. Nevertheless, these benefits
occurred at the expense of an increased risk of hyperkalemia,
which was more common in patients with reduced baseline
eGFR and those with WRF, particularly when randomized
to spironolactone. These findings suggest that patients with
HF and renal dysfunction still benefit from an MRA yet
argue that close monitoring of electrolytes is warranted in
this setting.
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